These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 32667213)

  • 41. Local wound care and topical management of hidradenitis suppurativa.
    Alavi A; Kirsner RS
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S55-61. PubMed ID: 26470618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
    Markota Čagalj A; Marinović B; Bukvić Mokos Z
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [CME Dermatology 23: Hidradenitis suppurativa].
    Dahmen RA; Lautenschlager S
    Praxis (Bern 1994); 2021; 110(7):363-372. PubMed ID: 34019444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hidradenitis suppurativa in a prepubertal girl.
    Lopes S; Gomes N; Trindade E; Azevedo F; Magina S
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Sep; 28(3):139-141. PubMed ID: 31545394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
    Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
    J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
    Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
    Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
    Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
    Guermazi D; Shah A; Yumeen S; Saliba E
    Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
    Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
    Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
    Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
    Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.
    Świerczewska Z; Lewandowski M; Surowiecka A; Barańska-Rybak W
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Target molecules for future hidradenitis suppurativa treatment.
    Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; Del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP
    Exp Dermatol; 2021 Jun; 30 Suppl 1():8-17. PubMed ID: 34085329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
    Giuffrida R; Cannavò SP; Coppola M; Guarneri C
    Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.